Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04739072 · ClinicalTrials.gov registry record
Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study
A clinical trial of Colorectal Adenocarcinoma and Stage III Colorectal Cancer AJCC v8, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 10
- Study locations
NCT04739072 is a study of Colorectal Adenocarcinoma and Stage III Colorectal Cancer AJCC v8 that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 1,000 participants, above the 266-participant average among 19 other Colorectal Adenocarcinoma trials with a reported enrollment target (276% higher). The trial reports 10 study locations across 6 states.
The verdict
NCT04739072, a study of Colorectal Adenocarcinoma and Stage III Colorectal Cancer AJCC v8, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 10
- Study locations
Study Summary
This study investigates if circulating tumor DNA (ctDNA) and other tumor-related molecules/chemicals released in the blood can help doctors predict if colorectal cancer may come back or spread. Tumors shed DNA and other cancer related chemicals into the blood that can be identified and studied further to provide information about the cancer. Information gathered from this study may help researchers better understand if ctDNA found in the blood can predict whether colorectal cancer may come back or spread.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Electronic Health Record Review
Study Locations (10)
Texas
- UT Southwestern/Simmons Cancer Center-Dallas - Dallas
- Houston Methodist Cancer Center - Houston
- M D Anderson Cancer Center - Houston
- UT Health San Antonio MD Anderson Cancer Center - San Antonio
- Baylor Scott & White Research Institute - Temple
Arizona
- Banner - MD Anderson Cancer Center - Gilbert
Florida
- Baptist- MD Anderson Cancer Center - Jacksonville
Hawaii
- The Queen's Medical Center - Honolulu
Idaho
- St. Luke's Cancer Institute - Boise
New Jersey
- Cooper Hospital UNIV MED CTR. - Camden
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2019-11-22 |
| Est. Completion | 2025-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04739072
The ClinicalTrials.gov registry entry for NCT04739072 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 266-participant average among 19 other Colorectal Adenocarcinoma trials with a reported enrollment target (276% higher). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Colorectal Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Biospecimen Collection is the first listed.
NCT04739072 reports 10 study locations spanning 6 distinct geographic areas - top geographies include Texas, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT04739072 about?
NCT04739072 is a clinical study titled "Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study". This study investigates if circulating tumor DNA (ctDNA) and other tumor-related molecules/chemicals released in the blood can help doctors predict if colorectal cancer may come back or spread. Tumors shed DNA and other cancer related chemicals into the blood that can be identified and studied furth...
What is the current status of trial NCT04739072?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2019-11-22. Estimated completion is 2025-12-31.
What conditions does trial NCT04739072 study?
This clinical trial studies the following conditions: Colorectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8.
What interventions are being tested in trial NCT04739072?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Electronic Health Record Review (OTHER).
Who is sponsoring clinical trial NCT04739072?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04739072 being conducted?
This trial has 10 study locations across Arizona, Florida, Hawaii, Idaho, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
RECRUITING · Phase 1
-
Early Onset Colorectal Cancer Detection
RECRUITING
-
Stage II/III Colorectal Cancer Recurrence
RECRUITING
-
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
RECRUITING · Phase 1
-
A Feasibility Study of Mass-Based Response Drug Screening to Guide Personalized Hyperthermic Intraperitoneal Chemotherapy for High-Grade Appendiceal and Colorectal Adenocarcinoma With Peritoneal Metastasis
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.